Glen Harbor Capital Management’s Haemonetics HAE Stock Holding History

Glen Harbor Capital Management’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$1.54M	Buy	12,240 +408	+3%	+$51.8K	0.03%	381
2019 Q2	$1.42M	Hold	11,832	–	–	0.03%	395
2019 Q1	$1.03M	Buy	11,832 +408	+4%	+$37.1K	0.02%	462
2018 Q4	$1.14M	Hold	11,424	–	–	0.03%	403
2018 Q3	$1.31M	Buy	11,424 +2,516	+28%	+$260K	0.03%	420
2018 Q2	$799K	Hold	8,908	–	–	0.02%	496
2018 Q1	$652K	Hold	8,908	–	–	0.01%	541
2017 Q4	$517K	Buy	8,908 +1,530	+21%	+$80.6K	0.01%	633
2017 Q3	$331K	Buy	7,378 +748	+11%	+$31.1K	0.01%	732
2017 Q2	$262K	Buy	6,630 +3,060	+86%	+$126K	0.01%	794
2017 Q1	$145K	Hold	3,570	–	–	﹤0.01%	823
2016 Q4	$143K	Buy	+3,570	New	+$135K	﹤0.01%	787

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Glen Harbor Capital Management's HAE Position: Q3 2019 in Review

Glen Harbor Capital Management increased its Haemonetics (HAE) stake by 3.4% in Q3 2019, buying an estimated $51.8K and bringing the position to 12,240 shares worth $1.54M. The position accounts for 0.03% of the portfolio, ranked #381.

Glen Harbor Capital Management first reported a position in HAE in Q4 2016 and has held it in 12 quarters since. 275 funds tracked by Wall St. Rank hold HAE as of Q3 2019.

Glen Harbor Capital Management held 12,240 shares of Haemonetics worth $1.54M as of Q3 2019.
Glen Harbor Capital Management bought 408 Haemonetics shares in Q3 2019, an estimated $51.8K.
Haemonetics made up 0.03% of Glen Harbor Capital Management's portfolio in Q3 2019, its #381 holding.
Glen Harbor Capital Management first reported a position in Haemonetics in Q4 2016 and has held it in 12 quarters since.
275 funds tracked by Wall St. Rank held Haemonetics as of Q3 2019.

Based on Glen Harbor Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.